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ABSTRACT
Introduction: Hereditary Haemorrhagic Telangiectasia (HHT) is as an autosomal dominant trait char-
acterized by frequent nose bleeds, mucocutaneous telangiectases, arteriovenous malformations (AVMs)
of the lung, liver and brain, and gastrointestinal bleedings due to telangiectases. HHT is originated by
mutations in genes whose encoded proteins are involved in the transforming growth factor β (TGF-β)
family signalling of vascular endothelial cells. In spite of the great advances in the diagnosis as well as in
the molecular, cellular and animal models of HHT, the current treatments remain just at the palliative
level.
Areas covered: Pathogenic mutations in genes coding for the TGF-β receptors endoglin (ENG) (HHT1)
or the activin receptor-like kinase-1 (ACVRL1 or ALK1) (HHT2), are responsible for more than 80% of
patients with HHT. Therefore, ENG and ALK1 are the main potential therapeutic targets for HHT and the
focus of this review. The current status of the preclinical and clinical studies, including the anti-
angiogenic strategy, have been addressed.
Expert opinion: Endoglin and ALK1 are attractive therapeutic targets in HHT. Because haploinsuffi-
ciency is the pathogenic mechanism in HHT, several therapeutic approaches able to enhance protein
expression and/or function of endoglin and ALK1 are keys to find novel and efficient treatments for the
disease.
ARTICLE HISTORY
Received 31 May 2017
Accepted 7 August 2017
KEYWORDS
HHT; endoglin; ALK1;
haploinsufficiency; bleeding;
angiogenesis; AVM;
bevacizumab; thalidomide
1. Clinical symptoms and histological findings in
hereditary hemorrhagic telangiectasia
Hereditary hemorrhagic telangiectasia (HHT) is an extremely
challenging disorder both to understand and manage and
spans a vast range of clinical and scientific disciplines. It is an
autosomal-dominant vascular disease characterized by fre-
quent nose bleeds, mucocutaneous telangiectases, arteriove-
nous malformations (AVMs) of the lung, liver and brain, as well
as involvement of the gastrointestinal (GI) tract associated with
GI bleedings due to telangiectases. Both AVMs and telangiec-
tases have in common the lack of intervening capillaries leading
to a direct connection between arteries and veins. The cuta-
neous telangiectases derive from a focal dilatation of the post-
capillary venule in the upper horizontal plexus [1]. An in silico
reconstruction of serial sections suggests that the dilated post-
capillary venules enlarge, connect with dilated arterioles with
loss of the intervening capillary bed, and form arteriovenous
shunts. Microscopic telangiectasia is observed not only in the
skin but also in other vascular beds such as the pulmonary
circulation where they may cause low grade intrapulmonary
right–left shunting detectable by contrast echocardiography in
the absence of macroscopic vascular abnormalities [2,3]. HHT is
a highly penetrant disorder where most patients present age-
dependent symptoms. Although infants are occasionally
severely affected, the proper diagnosis is often not reached
until adolescence or later. Telangiectases close to the surface
of the skin and mucous membranes are fragile and frequently
rupture and bleed upon slight trauma. The most common
clinical manifestation in more than 90% of patients is sponta-
neous and recurrent nosebleeds (epistaxis) beginning on aver-
age at age 12 years. In addition, approximately 25% of HHT
patients show GI bleeding, which usually presents after the age
of 50 years. Large AVMs often cause symptoms when they occur
in the brain, liver, or lungs, whereas complications from bleed-
ing or shunting may be sudden and catastrophic. The pheno-
type of each HHT patient develops differently depending on
their repertoire of susceptibility genes and/or environmental
triggers to which each individual is exposed. Diagnosis of HHT
follows the Curaçao Criteria, a widely accepted international
consensus diagnostic criteria [4,5]. It is based on the presence of
(1) nose bleeds, (2) cutaneous or mucosal telangiectases, (3)
visceral AVMs, and (4) family history. Thus, an individual has a
diagnosis of ‘definite HHT’ if three criteria are present, ‘sus-
pected HHT’ if two are present, and ‘unlikely HHT’ if only one
is present [2,3]. Once an index case has been characterized
within a family, a shortcut to the suspected diagnosis of HHT
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can also be made by identifying the familial pathogenic variant
in an individual.
2. Genetics of HHT and the TGF-β-signaling pathway
So far, all known genes whose mutations cause HHT are found
within the transforming growth factor-ß (TGF-β)-signaling path-
way. Mutations in the membrane TGF-β receptors endoglin
(ENG) and activin A receptor type II-like 1 (ACVRL1, also known
as ALK1) cause HHT1 (MIM 131195) and HHT2 (MIM 601284)
variants, respectively. Interestingly, these two genes, ENG or
ACVRL1, are mutated in over 80% of patients with HHT [6–10].
In addition, a combined syndrome of juvenile polyposis (JP) and
HHT was reported to be caused by mutations in MADH4 (also as
SMAD4) that encodes a transcription factor (Smad4) of the TGF-β-
signaling pathway [11]. This combined syndrome (JP-HHT; MIM
600993) occurs only in approximately 2% of HHT patients.
Recently, mutations in BMP9 (GDF2), a member of the TGF-β
family able to interact with endoglin and ALK1, have also been
shown to cause an HHT-like phenotype [12], which has been
named as the HHT5 variant of the disease (MIM 615506). Overall,
all the HHT variants share common symptoms, but they differ
from each other in the frequency of the specific vascular lesions.
For example, the frequency of pulmonary AVMs in HHT2 is much
lower than in HHT1 patients, whereas liver AVMs are more
frequent in HHT2 than in HHT1 patients. Because of the high
penetrance of the disease, given an index case within the family,
the molecular genetic testing of ENG, ACVRL1, SMAD4, and GDF2
can be used as a highly predictive molecular diagnosis of the
other family members. Interestingly, several studies have con-
cluded that a genetic screening strategy with targeted clinical
screening is cheaper than conventional clinical screening, result-
ing in a reduction of the number of clinical tests for family
members who do not have HHT [13].
Intrafamilial phenotypic variability has been reported in HHT,
suggesting that clinical penetrance and severity of the disease
are modulated by additional genetic factors, also called genetic
modifiers [7]. These determinants may include gene mutations/
polymorphisms that are not able to fully disrupt the function of
the encoded protein and are not sufficient to cause disease by
themselves. For example, the ACVRL1 c.314-35A>G polymorph-
ism is associated with pulmonary, liver, and brain AVMs in HHT1,
but not in HHT2 patients [14], whereas the ENG rs10987746
intronic polymorphism correlates with pulmonary AVMs in
HHT1 patients [15]. In addition, variants of novel modifier
genes such as protein tyrosine phosphatase non-receptor type
14 (PTPN4) and a disintegrin and metalloprotease 17 (ADAM17)
appear to influence the development of AVMs in HHT and can
potentiate a TGF-β-regulated vascular disease [16,17]. Further
genomic analysis of HHT families with phenotypic variability, as
well as those families with compelling evidence of an HHT dis-
order but without identifiable mutations in the known HHT
genes, should be useful to identify new genes with pathobiolo-
gical, diagnostics, and therapeutic implications in HHT. In this
context, the use of whole exome and genome testing and multi-
gene next-generation sequencing may contribute to explain a
heterogeneous spectrum of the HHT phenotype [7].
Because genes mutated in HHT encode protein components
of the TGF-β-signaling pathway, its perturbation appears to be at
the basis of HHT pathogenesis. Members of the TGF-β family such
as TGF-βs, BMPs, activins, nodals, GDFs, and inhibins acting as
ligands of specific receptors regulate diverse cellular functions,
such as cellular proliferation, differentiation, and apoptosis. These
ligands of the TGF-β family exert their action through binding to a
heteromeric complex of type I and type II TGF-β serine/threonine
kinase receptors [18]. Signaling can be propagated through a
cascade of protein phosphorylations via the canonical Smad-
dependent pathway, in which the gene products of the three
classical HHT genes (ENG, ACVRL1, SMAD4) and GDF2 function. As
endoglin and ALK1 are predominantly expressed in endothelial
cells, these are widely accepted as the HHT target cells, where
mutations in HHT genes may lead vascular lesions. Overall, ligand
binding activates a TGF-β type II receptor, which in turn phos-
phorylates a type I receptor (TβRI). Once activated, the type I
receptor phosphorylates and activates the receptor-associated
(R)-Smads including Smads 1/2/3/5 and 8. Then, phosphorylated
R-Smads bind to Smad4 and translocate to the nucleus, to reg-
ulate the transcriptional activity with coactivators and corepres-
sors. This TGF-β-signaling pathway is regulated by a negative
feedback loop via the inhibitory Smads (Smad6 and Smad7)
which target R-Smads for degradation. In most cell types, the
TGF-β type II receptor signals through ALK5 (TβRI) via Smad2/3,
but in endothelial cells, it can also signal through ALK1 (TβRI) via
Smad1/5/8. Remarkably, BMP9 is able to specifically bind ALK1
and endoglin [19–21]. A schematic representation of the HHT-
Article highlights
● Hereditary hemorrhagic telangiectasia (HHT) presents frequent nose
bleeds, mucocutaneous telangiectases, arteriovenous malformations
of the lung, liver and brain, and gastrointestinal bleedings. The
current treatments of this disease remain just at the palliative level.
● Heterozygous mutations in several genes whose encoded proteins
(endoglin, ALK1, BMP9, Smad4) are involved in the same TGF-beta
signaling pathway of endothelial cells, can lead to classical HHT or
HHT-like phenotypes through a pathogenic mechanism of
haploinsufficiency.
● The majority of patients with HHT have mutations in endoglin (HHT1)
or ALK1 (HHT2) genes; therefore, endoglin or ALK1 represent poten-
tial and preferential therapeutic targets to find novel treatments for
the disease.
● Many of the current pharmacological strategies appear to target the
expression or function of endoglin/ALK1 in endothelial cells, includ-
ing their involvement in angiogenesis, pericyte recruitment, cell pro-
liferation/apoptosis, and expression and function of endothelial nitric
oxide synthase, among others.
● Overall, the current pharmacological treatments are not always effec-
tive and some of them display adverse side effects. Consequently,
there is a need to find novel and better drug treatments.
● The recent generation of new HHT1 and HHT2 animal models are a
valuable tool to screen for novel candidate drugs previously identi-
fied as promising modulators of endoglin/ALK1 expression and
function.
● Whole exome and genome testing and multi-gene next generation
sequencing (NGS) of HHT families with phenotypic variability, as well
as those families with compelling evidence of an HHT disorder but
without identifiable mutations in the known HHT genes, should be
useful to identify new genes with pathobiological, diagnostics and
therapeutic implications in HHT.
This box summarizes key points contained in the article.
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signaling pathway within the TGF-β system of endothelial cells is
shown in Figure 1. Identifying new components on the roadmap
to this pathway may be useful in developing diagnostics and
therapeutics to target the pathogenesis of HHT.
3. Pathogenic mechanisms in HHT
Expression analysis of mutant endoglin and ALK1 proteins, the
clinical diagnosis associated with these pathogenic mutations,
and HHT-like phenotypes in heterozygous mice strongly sug-
gest haploinsufficiency of the respective protein as the cause
of HHT1 and HHT2 [6]. Over 1000 human ENG and ALK1 gene
variants linked to HHT have been reported (http://www.arup.
utah.edu/database/ENG/ENG_welcome.php). The majority of
HHT mutations analyzed so far lead to a mutant protein that
is either not expressed at all or retained intracellularly, sup-
porting a model of haploinsufficiency. However, in vitro stu-
dies have shown that some missense endoglin mutants can
heterodimerize with wild-type endoglin, interfering with its
expression at the cell surface, likely through a dominant nega-
tive effect [22,23]. Most of HHT1 missense mutations affect
buried hydrophobic residues and analysis of the 3D structure
of endoglin suggests that the majority of HHT1 mutations
impair its folding resulting in a reduced amount of functional
endoglin at the cell surface [24]. In addition, some missense
mutations in the ALK1 extracellular domain abrogate ligand-
dependent signaling in vitro [25], whereas functional analysis
in zebrafish of HHT2 mutations in the kinase domain of ALK1
has revealed different pathogenic mechanisms, including a
null phenotype via loss of protein expression or receptor
activity, as well as a dominant negative effect [26]. Overall,
haploinsufficiency is widely accepted as the cause of HHT1
and HHT2 pathogenicity and most of HHT mouse models are
haploinsufficient [6,27]. Nonetheless, haploinsufficiency by
itself does not account for the localized generation of vascular
in HHT patients. In this sense, it is intriguing why the vascular
HHT lesions appear only at distinct sites within certain organs,
rather than being present throughout the body and in all
organs/tissues. This paradox has been explained, as in many
other genetic diseases, postulating the need for an external
trigger, or second hit, such as vascular injury, inflammation,
infection, ischemia, angiogenic stimuli, or a second somatic
mutation in the healthy HHT gene that synergizes with endo-
glin haploinsufficiency to generate the lesion [28] (Figure 2).
Interestingly, some of these potential hits upregulate the
expression of endoglin and ALK1 (see item below), suggesting
that the function of ALK1 and endoglin is required under
those stressful settings. Experimental support for the second
hit hypothesis has been reported using a mouse with a con-
ditional mutation in Eng, demonstrating that AVMs develop
when an angiogenic stimulus is combined with endoglin
depletion in the vasculature of the neonatal retina [27,29].
Similarly, wounding or stimulation with the angiogenic vascu-
lar endothelial growth factor (VEGF) can induce vessels to
develop skin AVMs in Alk1-deficient mice [30–32].
Conversely, VEGF neutralization can prevent and normalize
AVMs in a mouse model for HHT2 [33]. Thus, in the haploin-
sufficient HHT setting subjected to the second hit, protein
levels of endoglin or ALK1 may not reach the minimum
threshold to exert their optimal function and this may be
critical to generate the vascular lesion (Figure 2). Of note, a
somatic mutation in the healthy HHT allele may also lead to a
critical drop in the endothelial function, as suggested by the
inducible HHT gene knockout animal models [27]. However,
the existence of a second somatic mutation in the vascular
lesions of HHT patients has not been demonstrated yet. In
summary, targeting gene expression and function of endoglin
and ALK1 appears essential to counteract HHT
haploinsufficiency.
4. Targeting gene expression of endoglin and ALK1
Endoglin and ALK1 are expressed in endothelial cells, which
are the primary cell target in HHT [27,28,34,35]. In resting
endothelial cells, endoglin is expressed at low levels, but it is
highly upregulated when these cells are actively proliferating
at sites of active angiogenesis and during embryogenesis
[28,34,36]. Comparative expression studies of the endothelium
in lung vessels have shown that endoglin and ALK1 have
distinct expression patterns in the pulmonary vasculature
and are only coexpressed in the distal (precapillary) arteries,
Figure 1. HHT and the TGF-β signalling pathway in endothelial cells. BMP9,
and probably other members of the TGF-β family, bind to an endothelial cell
surface receptor complex composed by the type I (R-I) receptor named ALK1
and the type II (R-II) receptor, both exhibiting serine/threonine kinase activity, as
well as the auxiliary receptor endoglin. The combinatorial heterodimeric asso-
ciation between different R-I and R-II determines the specificity of the ligand
signalling. Upon ligand binding, the R-II transphosphorylates ALK1, which sub-
sequently propagates the signal by phosphorylating the receptor-regulated
Smad (R-Smad) family of proteins Smad1/5/8. Once phosphorylated, R-Smads
form heteromeric complexes with a cooperating homologue named Smad4, and
translocate into the nucleus where they regulate the transcriptional activity of
different target genes [18]. BMP9, Endoglin, ALK1 and Smad4 proteins are
encoded by GDF2, ENG, ACVRL1 and MADH4 genes, whose pathogenic muta-
tions give rise to HHT5, HHT1, HHT2 and JPHT, respectively. BMP, bone mor-
phogenetic protein; GTM, general transcription machinery. Adapted from
McDonald et al. [7].
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distal veins, and capillaries, consistent with the tendency for
pulmonary AVMs to form in the distal pulmonary vessels in
HHT [37]. A regulatory region of the ALK1 is sufficient for
endothelial expression in arteries feeding ischemic tissues
[38]. In addition to endothelial cells, other cell lineages such
as macrophages and cells closely related to the vascular sys-
tem, such as smooth muscle cells of atherosclerotic plaques
and cardiac fibroblasts, can express at lower levels endoglin
and/or ALK1 at their surface [28,39–42]. Several studies have
analyzed the specific regulated expression of ENG and ALK1 at
the transcriptional level. The human endoglin and ALK1 pro-
moters do not contain TATA or CAAT transcription initiation
boxes, but guanine-cytosine (GC)-rich regions with consensus
sites for Sp1 which drive their basal transcriptional activity
[43–45]. Upregulated expression of endoglin was found in
inflamed or infected tissues, healing wounds, psoriatic skin,
synovial arthritis, upon vascular injury, and in tumoral vessels
[28,46,47]. Moreover, ALK1 is highly expressed in the vascular
structures of the embryo and markedly upregulated in
response to several angiogenic stimuli [35,37,48,49]. A variety
of stimuli have been reported to increase endoglin or ALK1
expression in activated vessels, including hypoxia, shear stress,
vascular injury, inflammation, and some related cytokines
(Figure 3). For example, endoglin expression is upregulated
after ischemia in the heart, kidney, and hind-limbs, as well as
upon arterial injury [47,50]. Under hypoxic conditions, the
hypoxia-inducible factor-1 (HIF-1) complex binds a functional
consensus hypoxia-responsive element in the endoglin gene
promoter [51]. TGF-β1 signaling, via Smad transcription fac-
tors, also potently stimulates endoglin expression [43,44].
Interestingly, BMP9, another member of the TGF-β family
mutated in HHT5, can also enhance the expression of endoglin
[52]. Whereas the hypoxic environment moderately enhances
endoglin transcription, addition of TGF-β1 under hypoxic con-
ditions results in a transcriptional cooperation between both
signaling pathways, leading to a marked stimulation of endo-
glin expression. This synergic stimulation involves the forma-
tion of a transcriptional multicomplex containing Smad3/
Smad4, Sp1, and HIF-1 [51]. In addition, endoglin expression
can be enhanced by the hypoxia-induced pathway involving
reactive oxygen species (ROS) which, in turn, oxidize choles-
terol yielding oxysterols. Then, oxysterols associate with the
nuclear receptor liver X receptor alpha (LXR), which binds to
LXR response elements on the endoglin promoter [53]. As a
member of the nuclear hormone receptors (NHRs) family, LXR
is a transcription factor that works in concert with other family
members to regulate gene expression. Some examples of
NHRs are the retinoid acid receptor, the retinoid X receptor,
or the vitamin D receptor. Among the ligands for NHRs are bile
acids, retinoids, steroid hormones, thyroid hormone, and vita-
min D. Of note, consensus vitamin D- and estrogen-responsive
elements have been identified in the endoglin gene promoter
[43]. The increased expression of endoglin can also be
obtained upon in vitro culture of endothelial cells using the
LXR synthetic agonist T0901317, suggesting the potential use
of this agonist in vivo to counteract endoglin haploinsuffi-
ciency [53,54]. Other stress conditions that may act as putative
second hits in HHT are vascular injury and shear stress. On
vascular injury, the transcription factor Krüppel-like factor 6
translocates to the nucleus of endothelial cells activating
endoglin, ALK1, and MMP-14 gene transcription, in synergy
with Sp1 [39,50,55] (Figure 4). In addition, endothelial cells
exposed to shear stress in vitro induce increased levels of
endoglin mRNA, but not ALK1 [58]. Of note, fluid shear stress
potentiates BMPs to activate ALK1 signaling, which correlates
with enhanced association of ALK1 and endoglin [59]. The
same authors also showed that this pathway mediates both
inhibition of endothelial proliferation and recruitment of vas-
cular mural cells, suggesting that a deficient endoglin/ALK1
pathway blocks flow-induced vascular stabilization and this
Figure 2. Hypothetical second hit model in HHT. The germline heterozygous mutation in the HHT gene leads to haploinsufficiency (First hit). A subsequent event
(Second hit) involves inflammation, hypoxia, neoangiogénesis, vascular injury, or a somatic mutation in the healthy HHT allele. Some of these events induce the
expression/activation of mediators, which generate a microenvironment where HHT protein levels are below the needed functional threshold. This drop in the HHT
functional protein can also be directly obtained after a second somatic mutation of the healthy HHT allele. The resulting deficiency in endothelial cells function leads
to the generation of vascular lesions.
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may be a molecular mechanism for development of HHT
lesions. Indeed, endoglin prevents AVMs by regulating flow-
induced cell migration and specification through VEGFR2 sig-
naling [60].
At variance with the upregulators of HHT genes, certain sti-
muli may induce their decreased expression. For example, in
endothelial cells, the inflammatory cytokine tumor necrosis fac-
tor-alpha (TNF-α) decreases endoglin protein levels [56,61]. It is
likely that this effect is mediated by proteases, which acting on
membrane endoglin can release a soluble form of the protein. In
this regard, the membrane-bound metalloprotease MMP-14
cleaves cell surface endoglin at a Gly–Leu bond in the juxtamem-
brane region, releasing most of its extracellular domain [54,57].
This catalytic activity can be enhanced when using antibodies to
endoglin, including TRC105, which enhance endoglin shedding
through direct coupling of endoglin and MMP-14 at the cell
surface to release soluble endoglin [62]. By decreasing the sur-
face expression of endoglin, these putative second hit factors
may enhance endoglin haploinsufficiency, thus favoring the loss
of endoglin function and, in turn, leading to vascular lesions.
5. Targeting endoglin and ALK1 protein function
Endoglin and ALK1 play a critical role in angiogenesis, and this
function is the target of many therapeutic approaches used in
HHT. Angiogenesis is a physiological homeostatic process by
which the body supplies oxygen and metabolites to the different
organs or tissues. This process involves the formation of new
vessels through two consecutive steps of activation and matura-
tion, both driven by endothelial cells, the target cells in HHT. Thus,
upon angiogenic stimulation, endothelial cells undergo prolifera-
tion, migration, budding, tube formation, maturation, and main-
tenance of quiescent endothelium. Thematuration phase involves
a progressive decrease in endothelial cell proliferation and the
recruitment of vascular mural cells, namely pericytes or vascular
smooth muscle cells (VSMCs). While pericytes serve to stabilize
capillaries, VSMCs are essential for arterial structure and function.
These processes are driven by a complex interaction of different
growth factors such as VEGF, fibroblast growth factor, and TGF-β
and their specific receptors, including endoglin and ALK1. Indeed,
the signaling pathway driven by these two receptors has been
shown tomodulate in vitro the TGF-β responses of endothelial cell
to proliferation and apoptosis [63,64] and its deficient expression
in HHT1 or HHT2 animal models leads to a markedly reduced level
of angiogenesis [27]. The protective role of the endothelial endo-
glin/ALK1 route in response to TGF-β-induced inhibition of cell
proliferation and apoptosis has been proposed to explain the
disappearance of the capillary bed in the haploinsufficient HHT
context [28]. Pericyte recruitment is a promising therapeutic target
in HHT [65]. Indeed, the involvement of endoglin [40–42] and
Figure 3. Modulators of gene expression and protein function of endoglin and ALK1. Left, gene expression of endoglin (Eng) and /or ALK1 can be upregulated
by different physiological stimuli including TGF-β1/BMP9, hypoxia, oxysterols or vascular injury through the activation of the transcription factors Smad, HIF-1α, LXR
or KLF6, respectively. Several drugs have shown to be able to stimulate endoglin and ALK1 expression (red rectangle), including raloxifene, bazedoxifene, the
synthetic agonist of oxysterols TO901317, the immunosuppresor FK506, atorvastatin and tranexamic acid. Some of these drugs stimulate HHT gene expression via
estrogen receptors (ER) or Liver X Receptors (LXR), as indicated. Right, endoglin and ALK1 proteins are involved in several functions and biological processes,
including angiogenesis, proliferation/apoptosis, leukocyte extravasation, cytoskeletal organization, vasodilatation, caveolae-dependent signaling, hemostasis,
immune system and pericyte recruitment, among others. Several drugs have been shown to modulate some of the endoglin/ALK1-dependent functions (blue
rectangles). Among these, the angiogenesis process appears as a preferential target where bevacizumab, thalidomide, metformin, sorafenib, GW771806, propranolol,
TRC105, Sol.Eng, dalantercept/ACE-041, and PF-03446962 may act displaying an anti-angiogenic effect. The procoagulant drugs tranexamic and aminocaproic acids
can act on the hemostasis process, whereas thalidomide stimulates the pericyte recruitment to the endothelium. The asterisks indicate those drugs which have been
used in the treatment of HHT patients. Full color available online.
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ALK1 [66] in the recruitment of vascular mural cells to the
endothelium has been reported. In the case of endoglin, this
process is due, at least in part, to the role of endoglin as an integrin
counter receptor in cell–cell adhesion [41] (Figure 5). Interestingly,
thalidomide, an antiangiogenic drug used in HHT therapy, has
been shown to act by enhancing pericyte recruitment to the
endothelium [67]. The adhesive activity of endothelial endoglin
has also been described to engage leukocyte [56] and platelet [68]
integrins, in turn regulating leukocyte extravasation and endothe-
lial-dependent hemostasis, respectively (Figure 5). In this regard,
the leukocyte infiltration has been postulated to be involved in the
vascular remodeling associated with the generation of HHT vas-
cular lesions [69–71]. Noteworthy, the adhesion of endoglin to
integrins is markedly enhanced under inflammatory conditions, as
well as in the presence of the chemokine CXCL12, which is able to
activate integrins to bind their ligands [41,56], suggesting that this
chemokine is a potential therapeutic target to activate the endo-
glin adhesive function. Moreover, several procoagulant therapies,
using tranexamic and aminocaproic acids, aim at regulating the
hemostasis process in HHT [2,72].
The relevance of angiogenesis as a therapeutic target in
HHT [73] is emphasized by the fact that several antiangiogenic
drugs have been used in the clinic, as well as in animal and in
vitro models of HHT (Figure 3). Among them, bevacizumab, a
humanized antibody to VEGF, and thalidomide have been
used for HHT patients [67,74]. Using an HHT2 animal model,
the oral antiangiogenic tyrosine-kinase inhibitors (TKIs) sorafe-
nib and GW771806 significantly improved anemia and GI
bleeding but were not effective for inhibiting the develop-
ment of wound-induced skin AVMs [75]. Based on its pleio-
tropic effects that include antiangiogenic properties,
metformin has been recently proposed as a prophylactic or
(a) (b)
(d)(c)
Figure 4. Hypothetical model of vascular injury as a second hit in HHT. In a healthy vessel with normal genotype (Eng+/+ or Acvrl1+/+) there is basal protein
expression of Eng and ALK1 and a crosstalk between vascular mural cells (VMCs), namely pericytes and vascular smooth muscle cells (vSMCs), and endothelial cells
(ECs) which maintain a well balanced angiogenesis (a). Upon vascular injury (second hit), KLF6 translocates from the cytoplasm to the nucleus and activates
endothelial genes such as endoglin [50], ALK1 [39], IL6 [39] and MMP14 [55]. MMP14 co-localizes with endoglin at the cell surface, triggering the release of soluble
endoglin. Soluble proteins such as IL6, endoglin and TGF-β are potential players in the cross-talk between ECs and VMCs during vascular repair. Under these
conditions, the injury-induced increased expression of endoglin or ALK1 allows for a proper vascular repair and remodeling (b). In a quiescent vessel with an HHT1
or HHT2 genotype (Eng± or Acvrl1+/-), although there is a decreased basal expression level of Eng and ALK1 proteins, this does not affect to the vessel stability (c).
However, upon vascular injury (second hit), KLF6 is able to unregulate the expression of the healthy HHT allele, but the final expression levels of endoglin or ALK1
are not able to reach the functional threshold required for the optimal vascular repair and remodeling, leading to the generation of AVMs. In addition, The HHT
haploinsufficiency status may be enhanced by a second somatic mutation in the healthy HHT allele [27] or by the proinflamatory TNF-α [56] or the
metalloproteinase MMP-14 [55,57], which may trigger the shedding of soluble endoglin and decrease the levels of membrane bound endoglin (d). This hypothetical
model can also apply when the second hit is inflammation, trauma, hypoxia, second somatic mutation, etc. Adapted from Gallardo-Vara et al. [55].
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curative therapy in HHT patients with lung involvement [76].
Moreover, the β-blocker propranolol, originally designed for
cardiological indications, is nowadays considered as an anti-
angiogenic drug for HHT therapy [77]. In fact, topical applica-
tion of timolol, a propranolol related compound with
nonselective beta blocker activity, decreases the severity and
frequency of epistaxis in HHT patients [78].
Because endoglin and ALK1 play a crucial role in angiogen-
esis, several related reagents have been generated aimed to
inhibit angiogenesis in pathologies associated with abnormal
angiogenesis. Among these, TRC105 is a chimeric monoclonal
antibody to endoglin that inhibits angiogenesis and causes
antibody-dependent cellular cytotoxicity and apoptosis of pro-
liferating endothelium [79]. TRC105 is currently used, alone or
in combination with other antineoplasic agents, in antiangio-
genic therapies of several types of cancer [79–81], including
more than 20 clinical trials involving solid tumors (https://
clinicaltrials.gov/). A soluble form of endoglin, encompassing
the extracellular domain of the membrane bound protein, also
displays antiangiogenic activity in vivo [19,41], an effect likely
mediated by sequestering endoglin-specific ligands as BMP9,
and thus antagonizing the function of membrane-bound
endoglin. Two ALK1-related pharmacological inhibitors, an
ALK1-Fc fusion protein (Dalantercept/ACE-041) and a human
antibody against the extracellular domain of ALK1 (PF-
03446962), have been used as an antiangiogenic strategy in
preclinical studies and are currently under clinical develop-
ment [35]. All these antiangiogenic reagents related to endo-
glin and ALK1 somehow antagonize the function of
membrane endoglin and ALK1, and in line with the antiangio-
genic strategy in HHT [73], it would be interesting and intri-
guing to test their potential therapeutic effects in this disease.
Endoglin and ALK1 interact with endothelial nitric oxide
synthase (eNOS) and regulate its activation [82–84]. Also,
mice heterozygous for Eng and Acvrl1 cause eNOS uncoupling
and generation of ROS, leading to impaired NO-mediated
vasodilatation. The mice showed age signs of pulmonary
arterial hypertension attributable to eNOS-derived ROS,
which was preventable by antioxidant treatment. In line with
these findings, the antioxidant N-acetyl-cysteine (NAC) has
been used to treat epistaxis in HHT patients with beneficial
effects [85].
Recently, it has been reported that mice lacking endoglin in
macrophages show an impaired immune response [86], which
could account for the higher rate of infectious diseases seen in
HHT [87]. Indeed, antibiotic prophylaxis to prevent infectious
outcomes is highly recommended when dental and invasive
procedures are required in HHT patients, primarily if pulmon-
ary AVMs are present or suspected [2,3,5].
Endoglin and ALK1 have been shown to regulate other
functions, widely discussed in previous reviews
[28,34,35,47,88,89], but apparently not targeted by HHT ther-
apeutic approaches.
6. Current and prospective therapies
6.1. Surgical therapies
Embolizations are used to close the AVMs, direct shunt con-
necting arterial blood, often present in lung up to 30–50% of
the cases, being more frequent in HHT1. Pulmonary AVMs with
feeding vessels 2–3 mm or greater in diameter require cathe-
ter-based occlusion. The devices used for embolization are
balloons, coils, and more recently Amplatzer® (St. Jude
Medical). Brain arteriovenous fistulae are less frequent than
pulmonary AVMs, up to 5–10% in HHT patients. Although
treatment of asymptomatic brain AVMs is controversial, in
some specific cases where the lesions are accessible for
Figure 5. Schematic diagram showing the role of endoglin in integrin-
mediated cell adhesion between ECs and vascular or circulatory cells. Left,
the endothelium (E) of the blood vessel is surrounded by vascular mural cells
(VMCs) and ECM proteins. Endothelial cells (ECs) and VMCs share a common
basal membrane (BM). During vascular development and stabilization, binding
of the homeostatic chemokine CXCL12 can activate VMCs integrins, leading to
binding of endothelial endoglin to integrins on VMCs. This endoglin-dependent
cellular adhesion may be involved in vascular development, stabilization and
permeability. Right, on inflammatory stimuli, different soluble factors are
released, including the chemokine CXCL12, leading to activation of integrins
present on leukocytes and platelets. Once activated, integrins bind to endoglin
present on the endothelial cell (EC) surface, allowing the extravasation and
migration of leukocytes to the inflammatory site and contributing to the
complex process of endothelium dependent hemostasis. In the HHT1 vascular
context subjected to inflammation/injury, endoglin haploinsufficiency leads to a
decreased binding of endothelial endoglin to integrins in VMCs, leukocytes and
platelets, leading to an impaired VSMC recruitment, leukocyte extravasation,
and endothelial-dependent hemostasis. The presence of other adhesion mole-
cules in endothelial cells has been omitted for simplification.
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embolization, they can be closed by onyx glue. Liver AVMs are
present in 30–70% of patients and are most frequent in HHT2.
Fortunately in most cases, liver AVMs remain asymptomatic.
However, liver transplantation is the only alternative when the
AVMs lead to serious impairment of the hepatic functionality
[2,5,90]. GI bleeding is treated with iron replacement therapy
and if needed with endoscopic ablation or surgical resection
of bleeding sites. When treating epistaxis, minor surgeries are
often used such as low penetrance laser closure by NYag or
Argon laser, and sclerotherapy near the telangiectases with
local injections of polydocanol or ethoxysclerol, which act as a
plug in the vessel [91]. Major surgeries include septodermo-
plasty or substitution of the nasal mucosa by skin of the upper
thighs, and the modified Young’s technique, which involves
the complete nose closure by sewing the internal nasal
mucosa.
6.2. Pharmacological therapies
Different options to control nose and gastric bleeding are
used [2,92], according to different strategies where endoglin
and ALK1 can be direct or indirect targets.
6.2.1. Antifibrinolytics
Although HHT is not a disease derived from a coagulation
failure, reinforcing coagulation versus fibrinolysis is useful.
The decrease of hemorrhages stabilizing the fibrin network
with antifibrinolytics is at the first line of epistaxis treatment.
Tranexamic acid is an antifibrinolytic agent 10-fold more
potent than ε-aminocaproic acid, and with longer half-life.
An increase of fibrinolytic activity on the wall of telangiectases
has been postulated [93], and ε-aminocaproic and tranexamic
acids may act by inhibiting fibrinolysis associated with telan-
giectases, in addition to increase the amount of endoglin and
ALK1 [72]. The only contraindication of antifibrinolytics would
be in those patients prone to thrombosis [94]. The first results
encouraged specialized centers to design multidisciplinary
clinical trials to assess the benefits of tranexamic acid in HHT
patients. Thus, the ATERO study demonstrated a significant
decrease in the duration of epistaxis in HHT patients taking
tranexamic acid in a multinational center study [95]. Another
report found that tranexamic acid reduces epistaxis in patients
with HHT in a double-blind crossover clinical trial phase IIIB
(clinical trial registration no. BfArM 141 CHC 9008-001 and
NCT01031992) [96].
6.2.2. Hormonal therapy: specific estrogen receptor
modulators (SERMs)
The observation that epistaxis often tend to increase after the
menopause in women led to the idea that estrogens might
exert a kind of protective effect concerning HHT-derived
bleeding in women. Next, the option of using specific estro-
gen receptor modulators (SERMs) to regulate the correspond-
ing NHRs, and not directly estrogens or progesterone, was
considered. Tamoxifen, well tolerated in postmenopausal
women, was successfully used in two clinical trials, signifi-
cantly decreasing epistaxis [97]. In the context of SERMs, the
efficacy and safety of raloxifene hydrochloride (a drug of the
same group as tamoxifen, and with advantages on bone
mineralization, cardiovascular and gynecological cancer pre-
vention) was assayed in a pilot study including 19 postmeno-
pausal women diagnosed with osteoporosis. The results
showed a significant decrease in frequency and quantity of
epistaxis, as well as a concomitant increase in hemoglobin
levels, after 6 months of raloxifene oral treatment (60 mg/
day) [98]. Studies on the biochemical basis of raloxifene action
on endothelial cells showed that estrogens, and raloxifene in
particular, are transcriptional activators of ENG and ACVRL1/
ALK1 gene promoters. Thus, the effective amount of endoglin
and ALK1 proteins, haploinsufficient products in patients from
HHT, is actually increased compensating, at least partially, for
the haploinsufficiency. Raloxifene hydrochloride was desig-
nated as the first orphan drug for the treatment of HHT-
derived bleeding in 2010 by the European Medicines Agency
(EMA) and the Food and Drug Administration (FDA) (EU/3/10/
730; FDA 21 U.S.C 360 bb). A more recent study with the third-
generation SERM bazedoxifene acetate yielded similar results
to those obtained with raloxifene [99]. Significant decreases in
the frequency and quantity of epistaxis, with an improvement
in the hemoglobin levels, were detected already after 1 month
of treatment, with a dose of 20 mg/day. Both SERMs, ralox-
ifene and bazedoxifene, are effective in upregulating endoglin
and ALK1 transcription. Bazedoxifene is more cost-effective
than raloxifene (dose of 20 vs. 60 mg/day, respectively) [99]
and has obtained the orphan drug designation for HHT in
2014 by the EMA (EU/3/14/1367).
6.2.3. Immunosuppresor (FK506)
The efficacy of tacrolimus (FK506) in increasing ENG and ALK1
expression was previously reported [100]. The rationale to
consider FK506 came from a case report of a patient with
HHT who received a liver transplantation after hepatic failure
due to liver AVMs. The liver was transplanted, and the immu-
nosuppressor FK506 was used to prevent the rejection. After
the first month of FK506 treatment, the internal and external
telangiectases, epistaxes, and anemia disappeared [101]. It
should be noted that continuous use of FK506 is not recom-
mended due to its suppressor effect on the immune system. In
vitro studies showed that FK506 increases the protein and
mRNA expression of ENG and ALK1 in cultured endothelial
cells and enhances the TGF-β1/ALK1-signaling pathway and
endothelial cell functions like tubulogenesis and migration
[100]. These results suggest that the mechanism of action of
FK506 involves a partial compensation of endoglin and ALK1
haploinsufficiency and might therefore be an interesting drug
for use in patients with HHT who undergo transplantation.
6.2.4. Atorvastatin
It has been published that atorvastatin (ATV) is able to
increase endoglin and eNOS expression and reduce plaque
size beyond its lipid-lowering effects by unknown mechanisms
[102]. After treatment of human umbilical vein endothelial
cells (HUVECs) with TNF-α, endoglin and eNOS protein expres-
sion was reduced. By contrast, ATV treatment increased endo-
glin and eNOS protein expression, while preventing TNF-α-
mediated downregulation of endoglin and eNOS protein
levels [102]. These results suggest that ATV treatment prevents
inflammation-reduced endoglin and eNOS expression in
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endothelial cells. On the other hand, ATV-induced eNOS
expression strongly depends on the proper expression of
endoglin in HUVECs. These findings might have implications
in pathological conditions characterized by reduced expres-
sion of endoglin and eNOS as for example in HHT. Thus, it
would be interesting to analyze whether hypercholesterolemic
HHT patients treated with statins show an epistaxis improve-
ment respect to untreated patients of the same age and
condition. Nonetheless, secondary effects of statins, like mus-
cle pain, increased risk of diabetes mellitus, and abnormalities
in liver enzyme tests should be considered.
6.2.5. Antiangiogenic approach
Decreasing the excess of abnormal vasculature present on the
nasal mucosa by anti-angiogenesis is a current strategy to
decrease bleeding in HHT. Protein levels of VEGF appear to
be elevated in HHT patients [103], a finding compatible with
the fact that partial ALK1 deficiency in vitro and in vivo results
in elevated VEGF expression [104]. Since VEGF is the main
angiogenic factor, these results suggest that the VEGF-depen-
dent angiogenic stimulus may be involved as a second hit in
the generation of HHT AVMs. In agreement with this hypoth-
esis, it has been shown that VEGF neutralization can prevent
and normalize AVMs in an HHT2 animal model [33]. This
experimental model represents an invaluable system to ana-
lyze the precise molecular mechanism of action of VEGF block-
ades, as well as for preclinical screening of drug candidates for
epistaxis and GI bleedings. Neutralization of VEGF with bev-
acizumab has been shown to be beneficial when treating HHT
patients with severe hepatic AVMs [74] or severe GI bleeding
[105,106]. However, in two independent studies, a bevacizu-
mab nasal spray treatment, compared with a placebo, did not
reduce epistaxis duration in HHT patients [107,108]. Of note,
certain undesired side effects on the use of bevacizumab have
been reported, including wounds that don’t heal, nausea,
vomiting, GI perforation, or constipation.
VEGF and PI3K/AKT signaling are increased on Alk1 dele-
tion and BMP9/10 ligand blockade [109], whereas genetic
deletion of the signal-transducing Vegfr2 receptor prevents
excessive angiogenesis but does not fully revert AVM forma-
tion. Conversely, pharmacological PI3K inhibition efficiently
prevents AVM formation and reverts established AVMs. Thus,
Alk1 deletion leads to increased endothelial PI3K pathway
activation, a route that may be a putative target for the
treatment of vascular lesions in HHT2. More recently, Kim
et al. [75] have evaluated the response of an adult Alk1-
inducible knockout (iKO) model to oral administration of the
different TKIs: sorafenib, sunitinib, erlotinib, and a pazopanib
analog (GW771806) on hemoglobin level, GI hemorrhages,
and formation of wound-induced skin AVMs. While sorafenib
and GW771806 significantly improved, yet erlotinib worsened,
anemia and GI bleeding in the Alk1-iKO model. However, none
of these TKIs were effective for inhibiting the development of
wound-induced skin AVMs. These results suggest that oral
delivery of antiangiogenic TKIs is selectively more effective
for GI bleeding than for mucocutaneous AVMs.
Thalidomide is another antiangiogenic drug, reported to
suppress levels of angiogenic and growth factors, including
VEGF, TNF-α, and bFGF. Lebrin et al. [67] have shown that
thalidomide reduces epistaxis by stimulating vessel matura-
tion through pericyte recruitment on the vasculature walls. A
pilot study on the clinical use of thalidomide in HHT has been
reported [110], indicating that thalidomide may have a posi-
tive effect on the number and severity of epistaxis. However,
adverse side effects of this drug, including severe malforma-
tions in infants born from mothers who had taken the drug
during pregnancy, depression, muscle weakness, constipation,
fainting, or dullness, should be taken into account.
The beta-blocker propranolol displays antiangiogenic prop-
erties and has been recently designed as an orphan drug for
the von Hippel Lindau disease (EU/3/17/1841). This drug, initi-
ally prescribed as antihypertensive and antiarrythmic, is cur-
rently the choice treatment for infantile hemangioma. An in
vitro study demonstrated the antiangiogenic and pro-apopto-
tic properties of propranolol on endothelial cells, suggesting
the use of propranolol for topical use in HHT [77]. Since then,
several reports have shown that topical application of nonse-
lective beta blockers, timolol and propranolol, decreases the
severity and frequency of epistaxis in HHT [78,111]. The poten-
tial systemic administration of this drug family of beta blockers
should consider its hypotensive activity.
6.2.6. Antioxidants
The effect of the antioxidant NAC was tested in large series of
43 HHT patients taking oral NAC 600 mg three times a day for
12 weeks, demonstrating a significant decrease in frequency
and severity of nose bleeds [85]. The improvement was most
evident in male patients and HHT1 patients with an ENG
mutation. In women and HHT2 patients with an ALK1 muta-
tion, only a trend for improvement was observed. Because of
the favorable side effects and the positive results with NAC,
these results may somehow justify a future randomized clinical
trial. Antioxidants are expected to counteract the harmful
effects of ROS and consequently may prevent or treat oxida-
tive stress-related diseases. Because oxidative stress contri-
butes to endothelial dysfunction in mouse models of HHT1
and HHT2 [112], it is possible that ROS contributes to preca-
pillary sphincter abnormalities, resulting in epistaxis. In this
regard, eNOS is coupled to the endoglin/ALK1/Hsp70 protein
complex for its proper enzymatic activity and the decrease of
endoglin or ALK1 uncouples eNOS, leading to less NO produc-
tion and an increase of O2 radicals [84]. In addition to a direct
effect of NAC neutralizing ROS, it has been described that NAC
can modulate the TGF-β-signaling pathway, in part, by driving
the monomerization of the disufide-linked dimer of native
endoglin [113].
6.3. Gene therapy
Despite great progress in drug development, effective thera-
pies for genetic diseases like HHT are still needed. In this regard,
gene therapy holds a promising future and can be used to
prevent, treat, or cure different disorders. It deals with the
replacement of the defective genes with their correct copies
to produce functional proteins, the inactivation of a mutated
gene or the introduction of a new gene into the patient. In the
two last decades, gene therapy has been driven by improve-
ments in viral and nonviral delivery strategies and many are
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now in clinical trials (www.genetherapynet.com). Currently,
gene therapy is a promising alternative in inherited disorders,
such as severe combined immune deficiency (ADA-SCID) [114],
chronic granulomatous disorder [115], and hemophilia [116].
Given the lack of effective treatments for HHT, gene therapy
may be considered a promising alternative as it is in other
hereditary pathologies. The first in vivo nonviral gene delivery
approach to treat HHT by gene therapy was performed by
inserting endoglin and ICAM-2 promoters upstream of human
endoglin cDNA in an expression plasmid. In vivo expression of
this transgene was clearly detected in several organs from adult
transgenic mouse [117]. After systemic delivery, high levels of
endoglin were detected in lung, spleen, and liver and upon
local gene delivery, endoglin was expressed in the endothelium
of vessels present in the dermis and subcutaneous tissue. These
results suggested that endoglin and ICAM-2 promoters can be
considered excellent tools to specifically deliver HHT genes in
vivo to the endothelium [117].
Several types of viruses have been engineered to deliver
genetic material therapeutically, including the classical retro-
virus, lentivirus, adenovirus, and adeno-associated viruses
(AAVs). Retroviruses were the first class of viruses to be har-
nessed for gene transfer, although this type of viral therapy is
full of serious safety concerns. CRISPR–Cas9 system is an alter-
native technology that allows the edition of genome using
programmable DNA nucleases packed in an AAV vector. This
novel gene editing tool offers a precise method to correct
DNA changes but implies a personalized gene therapy as
each family’s mutation would need to be managed individu-
ally [118]. Lentiviral vectors targeting endoglin have also been
used for endothelial cell-targeted therapy. This approach
allowed targeted gene transfer to endothelial cells with a
high degree of specificity in vitro [119]. Upon systemic injec-
tion, endoglin lentiviral vector specifically transduced liver
sinusoidal endothelial cells, but not other liver cells, and a
strong gene expression was detected [120]. Recently, it has
tested an innovative gene therapy strategy injecting an
adeno-associated viral vector serotype-9 expressing soluble
FLT1 (AAV9-sFLT1) into the brain to alleviate AVMs. sFlt1
binds to VEGF and therefore neutralizes VEGF pathogenic
effects in HHT-associated brain AVMs [121]. This viral vector
can potentially be developed into a safer therapy to reduce
not only brain AVMs but also those that appear in other
organs. One potential setback to the use of AAV vectors for
gene therapy is the presence of neutralizing antibodies gen-
erated upon natural exposure. In fact, patients with elevated
titers of these neutralizing antibodies are usually excluded
from the treatment with AAV vectors. In addition, patients
who have received AAV-based gene therapy may develop
antibodies to the viruses, thus making these individuals poorly
suited for retreatment with AAV vectors [122]. Much further
research is required to consider gene therapy a plausible
option for HHT patients.
6.4. Genetic modulators
Many of the identified HHT mutations in ENG and ACVRL1 are
premature termination codons or missense variants, which
prevent the proper synthesis of the functional protein.
Interestingly, the FDA and the EMA have approved several
innovative drugs, termed genetic modulators, which target
some genetic diseases by modulating the efficiency of the
mutant protein translation, yielding a more functional protein.
Among these drugs are selected antibiotics of the aminoglyco-
side family such as geneticin (G418), as well as multiple novel
synthetic molecules like ataluren [123,124]. The promising
results of ataluren in Duchenne muscular dystrophy and cystic
fibrosis [125] have prompted preclinical studies aimed to eval-
uate whether ataluren is able to read through the stop codons
in HHT1 and HHT2 mutations [126]; if successful, these studies
may lead to new and more effective therapies for HHT.
7. Conclusions
In HHT, clinical manifestations range from mild to life-threa-
tening and all patients require a coordinated multidisciplinary
approach. In recent years, there has been much progress in
the discovery of the genetic basis of HHT and the role of the
angiogenesis process in its pathogenesis. HHT spans a vast
range of scientific and clinical disciplines and is a challenging
disorder both to understand and to manage. Pathogenic
mutations in endoglin (HHT1) or ALK1 (HHT2) genes represent
a majority of HHT patients, and cellular and molecular
mechanisms underlying the generation of HHT vascular
lesions are being unraveled in HHT1 and HHT2 experimental
models. A wide range of pharmacological strategies has been
used to treat nose and GI bleedings, including antifibrinolytics,
estrogen receptor modulators, immunosuppresors, and anti-
oxidants. In recent years, there has been much excitement
about the use of the antiangiogenic strategy with the VEGF
antagonist bevacizumab, whether administered intranasaly or
systematically. However, these drugs are not always effective,
relapses occur after withdrawal, and some of the drugs display
undesired secondary effects. Therefore, future research on the
identification of novel treatments using the available HHT
animal models should yield better therapies to improve the
work ability and quality of life of HHT patients. Also, exploring
the administration of the current drugs, not only as mono-
therapy but also in combination with other strategic com-
pounds or stimuli, is needed.
8. Expert opinion
To our current knowledge, HHT is caused by a deregulation of
the balance between pro-angiogenic and antiangiogenic fac-
tors that leads to the generation of mucocutaneous telangiec-
tases and AVMs in internal organs. There is ample and strong
evidence from in vitro and in vivo animal models, supporting
the involvement of endoglin and ALK1 in the angiogenic
process. Because pathogenic mutations in endoglin (HHT1)
or ALK1 (HHT2) genes involve approximately 80% of HHT
patients, studies to counteract endoglin or ALK1 haploinsuffi-
ciency are critical to discover new and better therapies. The
cellular and molecular mechanisms underlying the generation
of HHT vascular lesions are quickly being unraveled in HHT1
and HHT2 experimental models, with some data focusing on a
defective response to angiogenic stimuli in particular settings
where the VEGF system plays a critical role. In fact,
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neutralization of VEGF with bevacizumab, a humanized anti-
VEGF monoclonal antibody previously used in cancer therapy,
can prevent and normalize AMVs in an HHT mouse model. In
this line, treatment with bevacizumab of severe GI bleeding in
HHT has been achieved with beneficial effects. There are also
some HHT case reports on temporal reversal of liver transplan-
tation with bevacizumab administration, suggesting that this
drug may be useful in liver failure due to hepatic AVMs.
Nonetheless, since HHT patients who have undergone liver
transplantation have a long time survival, bevacizumab does
not appear as replacement of liver transplantation but may
probably serve to delay it. Also, nasal spray treatment with
bevacizumab of spontaneous epistaxis has yielded poor
results. Blood pressure is a well known on-target effect for
anti-VEGF drugs, and adverse events and complications asso-
ciated with systemic bevacizumab treatments include hyper-
tension, headache, nausea or vomiting, asthenia, diarrhea, and
rash. Normalization of the HHT vasculature can also be
achieved with thalidomide, another antiangiogenic drug,
which has been shown to reduce nose bleeds, likely by pro-
moting pericyte recruitment to the endothelium and vessel
maturation. Adverse side effects of thalidomide treatment
include nausea, drowsiness, dizziness, and peripheral neuro-
pathy. Although current results show that thalidomide may be
a treatment choice for recurrent nosebleeds in HHT patients,
the side effects should be considered. A novel derivative of
thalidomide, known as pamolidomide (3-amino-thalidomide),
was recently approved by the US FDA as a treatment for
relapsed and refractory multiple myeloma [127]. It is therefore
tempting to investigate the therapeutic effect of pamolido-
mide in HHT. Other pharmacological strategies include antifi-
brinolytics (tranexamic and aminocaproic acids), estrogen
receptor modulators (raloxifene and bazedoxifene), the immu-
nosuppresor tacrolimus, and the antioxidant NAC, which can
counteract haploinsufficiency by upregulating endoglin and
ALK1 expression or function.
This review focuses on the new evidence and concepts of
this complex condition, placing these in context for both
clinicians and scientists. Unfortunately, the current pharma-
cological treatments remain at the palliative level and some
of them display adverse side effects. Overall, there is no fully
effective registered drug for HHT. Therefore, novel therapeu-
tic targets need to be explored. To this end, currently avail-
able HHT1 and HHT2 animal models are a valuable tool to
screen for and identify novel drugs. While the pharmacologi-
cal treatments for epistaxis and GI bleeding, or embolother-
apy in pulmonary AVMs, alleviate the symptoms in HHT
patients, achieving the reversion of the vascular lesions
remains as an important challenge. It can be postulated
that this reversion may be triggered by an angiogenic cue
to facilitate a proper vascular remodeling leading to the
disappearance of telangiectasia and AMVs. This process
would be somehow opposite to the generation of vascular
lesions that occurs in an HHT haploinsufficient background,
where a second hit is involved. In this case, however, in order
to make sure that the second hit induces a proper remodel-
ing, HHT haploinsufficiency should be minimized by increas-
ing the expression or functional activity of the corresponding
HHT protein. As described above, several stimuli can enhance
the expression of endoglin or ALK1, including TGF-β, BMP9,
vascular injury, hypoxia, oxysterols, raloxifene, bazedoxifene,
and tranexamic acid, and may serve to this purpose.
Experiments with HHT cellular and animal models have
yielded additional putative modulators of endoglin/ALK1
function. Among these are (1) PI3K inhibitors which inhibit
AVM formation; (2) TKIs, which show beneficial effects on
anemia and GI bleeding; (3) integrin activators as CXCL12,
which allows binding of endothelial endoglin to the corre-
sponding integrins on leukocytes, pericytes, or platelets; (4)
BMP9 which acts upstream of endoglin and ALK1 in the HHT-
signaling pathway and its blockade aggravates HHT symp-
toms; (5) oxysterols and other agonists of nuclear LXR, which
can upregulate ENG expression; and (6) compounds such a
propranolol, soluble endoglin, TRC105, and Dalantercept/
ACE-041, all with antiangiogenic properties. Gene therapy is
also a good option to target endoglin or ALK1 expression to
the vascular endothelium, although this strategy has been
poorly explored and deserves further investigation. Overall,
we conclude that the accumulated knowledge about the
expression and function of endoglin and ALK1, as well as
the currently available HHT1 and HHT2 animal models, offer
promising opportunities to screen for and identify better
treatments able to normalize the vascular lesions in HHT.
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